首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFSF4 |
| Uniprot No | P23510 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 52-183aa |
| 氨基酸序列 | QVSHRYPRIQSIKVQFTEYKKEKGFILTSQKEDEIMKVQNNSVIINCDGF YLISLKGYFSQEVNISLHYQKDEEPLFQLKKVRSVNSLMVASLTYKDKVY LNVTTDNTSLDDFHVNGGELILIHQNPGEFCVL |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFSF4(OX40L)重组蛋白的3篇参考文献概览：
---
1. **文献名称**: *"Recombinant OX40 ligand protein promotes differentiation of CD4+ T cells into effector T cells"*
**作者**: Croft M et al.
**摘要**: 研究利用大肠杆菌表达系统制备重组TNFSF4/OX40L蛋白，验证其与受体OX40的结合活性，并证明该蛋白可体外增强CD4+ T细胞分化为Th1和Th2效应细胞，提示其在免疫调节中的作用。
2. **文献名称**: *"Engineering a soluble form of OX40L with improved stability and biological activity"*
**作者**: Wang Y et al.
**摘要**: 通过哺乳动物细胞表达系统优化重组TNFSF4的胞外区结构，获得高稳定性可溶性蛋白。实验表明该蛋白能有效激活OX40信号通路，在肿瘤免疫模型中增强抗PD-1疗法的效果。
3. **文献名称**: *"TNFSF4/OX40L recombinant protein exacerbates autoimmune arthritis by enhancing follicular helper T cell responses"*
**作者**: Kim J et al.
**摘要**: 在小鼠类风湿性关节炎模型中，注射重组TNFSF4蛋白显著增加了滤泡辅助T细胞(Tfh)的数量及自身抗体水平，揭示了TNFSF4在自身免疫疾病中的潜在病理机制。
---
注：以上文献信息为基于领域内典型研究的模拟概括，实际引用时请核实具体文献内容及来源。
**Background of TNFSF4 Recombinant Protein**
TNFSF4 (Tumor Necrosis Factor Superfamily Member 4), also known as OX40 ligand (OX40L) or CD252. is a type II transmembrane protein belonging to the TNF superfamily. It plays a critical role in immune regulation by interacting with its receptor, OX40 (CD134), primarily expressed on activated T cells. This ligand-receptor interaction provides co-stimulatory signals that enhance T-cell proliferation, survival, and cytokine production, particularly in settings of chronic inflammation, autoimmune diseases, and antitumor immunity.
Recombinant TNFSF4 protein is engineered using genetic technology, typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) or *E. coli*, depending on the desired post-translational modifications. The recombinant form often includes the extracellular domain of TNFSF4 (amino acids 51-200 in humans), omitting the transmembrane region to ensure solubility. It may be fused with affinity tags (e.g., Fc or His tags) for purification and functional studies.
As a research tool, TNFSF4 recombinant protein is widely used to investigate OX40/OX40L signaling in immune cell activation, tolerance, and disease mechanisms. In therapeutic contexts, it has been explored as an agonist to boost antitumor T-cell responses in cancer immunotherapy or as a target for neutralizing antibodies/inhibitors to dampen pathogenic T-cell activity in autoimmune disorders like rheumatoid arthritis or lupus.
Its production under stringent quality controls ensures high purity and bioactivity, making it valuable for both basic research and preclinical drug development. Studies continue to elucidate its dual role in immune regulation, balancing protective immunity and immunopathology.
×
